Teva launches Yaz generic in the US, triggering patent infringement suit by Bayer
This article was originally published in Scrip
Teva Pharmaceutical Industries has launched its own generic version of Bayer's oral contraceptive, Yaz (drospirenone plus ethinyl estradiol), in the US to be sold under the brand-name Gianvi. The move immediately triggered a patent infringement lawsuit from Bayer, which has accused Teva of infringing three patents that expire in June 2014. Yaz is the top-selling birth control pill in the US.